ethA韩国仁荷,katG ethionamide-resistant临床结核分枝杆菌分离株的基因座。

文章的细节

引用

复制到剪贴板

摩洛克医生,Metchock B,赛克斯D,克劳福德JT, Cooksey RC

ethA韩国仁荷,katG ethionamide-resistant临床结核分枝杆菌分离株的基因座。

Antimicrob代理Chemother。2003年12月,47 (12):3799 - 805。

PubMed ID

14638486 (在PubMed

]

文摘

乙硫异烟胺(乙)是一个公开的结构模拟药物异烟肼(INH)。这两种药物目标韩国仁荷,一种酶参与霉菌酸生物合成。异烟肼需要catalase-peroxidase (KatG)激活和突变KatG主要异烟肼耐药性机制。最近一种酶(EthA)能够激活乙已被确认。我们测序整个ethA 41 ETH-resistant结核分枝杆菌分离株的结构基因。我们还测序两个地区韩国仁荷和katG的全部或部分。ETH的麦克风和异烟肼测定为了副突变与耐药表型。15隔离被发现拥有ethA突变,为所有的ETH麦克风>或= 50 microg /毫升。ethA突变都是不同的,以前未报告的,分布在整个基因。在八个隔离,韩国仁荷结构基因的错义突变发生。 The ETH MICs for seven of the InhA mutants were > or =100 microg/ml, and these isolates were also resistant to > or =8 microg of INH per ml. Only a single point mutation in the inhA promoter was identified in 14 isolates. A katG mutation occurred in 15 isolates, for which the INH MICs for all but 1 were > or =32 microg/ml. As expected, we found no association between katG mutation and the level of ETH resistance. Mutations within the ethA and inhA structural genes were associated with relatively high levels of ETH resistance. Approximately 76% of isolates resistant to > or =50 microg of ETH per ml had such mutations.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
乙硫异烟胺	Catalase-peroxidase	蛋白质	结核分枝杆菌	未知的	其他/未知	细节
乙硫异烟胺	Enoyl——(酰基载体蛋白质)还原酶(NADH)	蛋白质	结核分枝杆菌	是的	抑制剂	细节